Core Viewpoint - RadNet, Inc. reported its financial results for the first quarter of 2025, highlighting a revenue increase despite challenges from severe weather and wildfires, and announced an acquisition of iCAD to enhance its AI-powered cancer detection capabilities [1][4][3]. Financial Performance - Total Company Revenue for Q1 2025 was $471.4 million, a 9.2% increase from $431.7 million in Q1 2024 [4][6]. - Adjusted EBITDA for Q1 2025 was $46.4 million, down 20.6% from $58.5 million in Q1 2024 [4][6]. - The Digital Health segment saw a revenue increase of 31.1%, reaching $19.2 million in Q1 2025 compared to $14.7 million in Q1 2024 [4][7]. Operational Highlights - Procedural volumes increased by 3.6% overall, with advanced imaging growing 1.26% year-over-year [4][10]. - PET/CT procedural volume surged nearly 23% compared to the same quarter last year, driven by growth in prostate and brain imaging [2][4]. - The company implemented TechLive™ remote scanning capabilities, enabling approximately 255 MRIs, and began testing this technology on ultrasound systems [2]. Acquisition and Strategic Initiatives - RadNet signed a definitive agreement to acquire iCAD, which will enhance its Digital Health division and support over eight million annual mammograms globally [3][4]. - The acquisition is expected to strengthen RadNet's position in AI-powered breast cancer screening and improve population health initiatives [3]. Revised Guidance - RadNet revised its full-year 2025 guidance, increasing the revenue range to $1,835 - $1,885 million and Adjusted EBITDA to $268 - $276 million [12][11]. Balance Sheet and Cash Flow - As of March 31, 2025, RadNet had a cash balance of $717 million and a leverage ratio of Net Debt to Adjusted EBITDA slightly above 1.0x [5]. - The company reported a net loss of $37.9 million for Q1 2025, compared to a net loss of $2.8 million in Q1 2024 [8][42]. Market Position - RadNet operates a network of 401 outpatient imaging centers across several states, making it a leading provider in the diagnostic imaging industry [16]. - The company employs over 11,000 individuals, including contracted radiologists and technologists [16].

LOS ANGELES, May 09, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Securities 2025 Healthcare Conference in Las Vegas, NV on Tuesday, May 13, 2025 at 5:00 p.m. Pacific Time. There will be simultaneous and archive ...

Core Viewpoint - RadNet, Inc. has announced a definitive merger agreement to acquire iCAD, Inc. in an all-stock transaction valued at approximately $103 million, representing a significant premium for iCAD stockholders [1][2]. Group 1: Merger Details - iCAD stockholders will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock they hold at the closing of the merger, equating to about $3.61 per share on a fully diluted basis [2]. - The transaction is expected to close in the second or third quarter of 2025, pending approval from iCAD stockholders and other customary closing conditions [3]. Group 2: Strategic Rationale - The merger aims to enhance patient diagnosis and outcomes in breast cancer detection through the combined capabilities of iCAD's ProFound Breast Health Suite and RadNet's DeepHealth AI-powered solutions [3]. - The acquisition will expand RadNet's existing network, which includes over 1,500 healthcare provider locations and facilitates over 8 million annual mammograms across 50 countries [3][5]. Group 3: Leadership Comments - Dr. Howard Berger, CEO of RadNet, emphasized the potential to improve global breast cancer diagnosis and outcomes through this merger [3]. - Dana Brown, CEO of iCAD, highlighted the opportunity to redefine disease detection and treatment, aiming to enhance access to advanced tools and improve patient care [3]. Group 4: Future Plans - Following the acquisition, iCAD will be integrated into RadNet's DeepHealth portfolio, which is expected to accelerate growth and leadership in cancer screening and artificial intelligence [5]. - RadNet plans to host an investor conference call to discuss the transaction details, indicating a commitment to transparency and stakeholder engagement [4][5].

RadNet (RDNT) Q4 2024 Earnings Call February 28, 2025 10:30 AM ET Company Participants Mark Stolper - Executive VP & CFOHoward Berger - Chairman, President & CEOJohn Ransom - Managing Director, Director of Healthcare ResearchAndrew Mok - Director Conference Call Participants David Macdonald - AnalystBrian Tanquilut - Equity Research Analyst - Healthcare ServicesLarry Solow - Partner & Managing director - Equity AnalystJim Sidoti - Analyst Operator Good day, and welcome to the RadNet Inc. Fourth Quarter twen ...